Thursday April 12, 2018 at 2:30 PM EDT (7:30 PM BST)
Tumor heterogeneity is a challenge in cancer research and drug development. Examination of cancer cell lines does not offer a comprehensive view of a tumor or tumor microenvironment. This is where it can be helpful to examine a patient derived xenograft (PDX) model of tumors. PDX models are typically implanted as dissociated cells or tumor fragments into immunodeficient mouse models which may then be used for in vivo efficacy studies, allowing you to accelerate your oncology research or drug discovery and development programs, including applications for preclinical drug screening, preclinical combination therapeutics screening, identification and analysis of biomarkers. Horizon Discovery, the sponsor of this Lab Tools webinar, offers cancer model collections as ungrafted PDX suspensions or as comprehensive in vivo efficacy studies.
Our team are on hand to help you discuss your next custom project: